NASDAQ$ALDX
Aldeyra Therapeutics Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported financial results for the first quarter, announced new clinical trials in systemic inflammatory diseases, and provided an update on ocular disease programs.
Aldeyra Therapeutics reported a net loss of $9.9 million for the first quarter of 2020, compared to a net loss of $15.6 million for the same period in 2019. The company is advancing its pipeline with new clinical trials in systemic inflammatory diseases and updates on ocular disease programs, while extending its cash runway into 2022.
- ADX-629 is expected to begin Phase 2 clinical trials in COVID-19 respiratory compromise, atopic asthma, and psoriasis in 2020.
- A Type C meeting is scheduled with the FDA to discuss remaining NDA requirements for reproxalap in dry eye disease.
- Results from the Phase 3 INVIGORATE Trial of reproxalap in allergic conjunctivitis are expected in the first half of 2021.
- The company's cash runway has been extended into 2022.
Headline financials
Revenue & EPS history
Aldeyra · Revenue · Quarterly
$0
Forward guidance
Aldeyra believes that its cash, cash equivalents, and marketable securities as of March 31, 2020 will be sufficient to fund currently anticipated operating expenses into 2022.
Tailwinds
- Completion of the Phase 3 INVIGORATE Trial for reproxalap
- Phase 2 clinical trials of ADX-629 in COVID-19-associated respiratory compromise
- Phase 2 clinical trials of ADX-629 in atopic asthma
- Phase 2 clinical trials of ADX-629 in psoriasis
- Continuation of Part 1 of the adaptive Phase 3 clinical trial in PVR contingent on patient enrollment
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+0.7%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
47%
24 / 51 earnings
Positive
+22.7%
Q4 2026
Best reaction
-14.1%
Q4 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +22.7% | -2.3% | -6.4% | |
| Q3 2025 | -2.5% | +10.2% | -2.3% | |
| Q1 2025 | +0.9% | -3.6% | +72.3% | |
| Q4 2024 | +4.5% | +4.4% | -71.5% | |
| Q3 2024 | +2.2% | -11.9% | -3.3% | |
| Q2 2024 | -10.7% | -12.7% | +46.1% | |
| Q1 2024 | -1.0% | -0.7% | -8.1% | |
| Q4 2023 | -7.9% | -23.5% | +20.1% | |
| Q3 2023 | +7.7% | +24.9% | +36.8% | |
| Q2 2023 | +0.8% | -6.6% | -5.0% | |
| Q1 2023 | +3.8% | +0.8% | +4.6% | |
| Q4 2022 | -2.6% | +6.6% | +34.2% | |
| Q3 2022 | +12.2% | +9.5% | +18.5% | |
| Q2 2022 | +15.4% | +24.0% | +11.2% | |
| Q1 2022 | -7.5% | -10.2% | +4.1% | |
| Q4 2021 | +18.4% | +19.4% | +9.1% | |
| Q3 2021 | +10.4% | +6.9% | -6.8% | |
| Q2 2021 | +11.1% | +8.4% | +4.3% | |
| Q1 2021 | +4.3% | +4.8% | +5.6% | |
| Q4 2020 | +3.6% | -3.1% | -0.3% | |
| Q3 2020 | -1.6% | -1.6% | +5.7% | |
| Q2 2020 | -4.4% | -11.4% | -21.6% | |
| Q1 2020 | -2.7% | +14.3% | +64.8% | |
| Q4 2019 | -10.0% | -27.6% | -15.4% | |
| Q3 2019 | -1.7% | +1.0% | -21.6% | |
| Q2 2019 | -4.2% | -0.7% | -9.4% | |
| Q1 2019 | -2.9% | -7.0% | -14.4% | |
| Q4 2018 | +2.3% | +20.2% | +15.1% | |
| Q3 2018 | -13.1% | -11.1% | -6.2% | |
| Q2 2018 | +8.4% | +5.6% | +10.5% | |
| Q1 2018 | +2.9% | +1.7% | +0.0% | |
| Q4 2017 | -14.1% | -14.7% | -1.8% | |
| Q3 2017 | +2.6% | +4.3% | +19.8% | |
| Q2 2017 | -7.4% | -6.4% | -10.6% | |
| Q1 2017 | +7.6% | +12.7% | +17.7% | |
| Q4 2016 | -2.9% | +1.0% | -15.5% | |
| Q3 2016 | +2.7% | -3.6% | -22.5% | |
| Q2 2016 | +0.3% | -2.8% | -3.8% | |
| Q1 2016 | -3.1% | — | — | |
| Q4 2015 | -1.4% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -5.3% | — | — | |
| Q1 2015 | -1.1% | — | — | |
| Q4 2014 | -3.7% | — | — | |
| Q3 2013 | +5.3% | — | — | |
| Q3 2014 | +5.5% | — | — | |
| Q2 2013 | +15.0% | — | — | |
| Q2 2014 | -6.3% | — | — | |
| Q1 2014 | -4.6% | — | — | |
| Q1 2013 | -4.6% | — | — | |
| Q4 2013 | -4.6% | — | — | |
| Q4 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro